- Home
- NAAS vs KYNB Comparison
NAAS vs KYNB Comparison
Compare NAAS & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | KYNB |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 31.9M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | NAAS | KYNB |
|---|---|---|
| Price | $2.30 | $7.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.3K | ★ 22.6K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $6.32 |
| 52 Week High | $4.54 | $9.58 |
Technical Indicators
Market Signals| Indicator | NAAS | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 51.47 |
| Support Level | $2.23 | $7.11 |
| Resistance Level | $2.70 | $7.52 |
| Average True Range (ATR) | 0.20 | 0.30 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 33.12 | 76.65 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.